Use of Urinary Biomarkers for Bladder Cancer Surveillance: Patient Perspectives

Journal of Urology

Volumn 177, Issue 4, 2007, Pages 1277-1282

  Yossepowitch, Ofer ^a   Herr, Harry W ^a   Donat, S Machele ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

biological; bladder; bladder neoplasms; cystoscopy; tumor markers

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ADULT; AGED; ANXIETY; ARTICLE; BLADDER CANCER; CANCER GROWTH; CYSTOSCOPY; DEMOGRAPHY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PAIN ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE; UNIVARIATE ANALYSIS; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CYSTOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; POPULATION SURVEILLANCE; URINARY BLADDER NEOPLASMS;

EID: 33947266447     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.11.066     Document Type: Article

References (16)

1. Holmang S., Hedelin H., Anderstrom C., and Johansson S.L. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 153 (1995) 1823
2. Scher H., Bahnson R., Cohen S., Eisenberger M., Herr H., Kozlowski J., et al., National Comprehensive Cancer Network. NCCN urothelial cancer practice guidelines. Oncology (Williston Park) 12 (1998) 225
3. Schrag D., Hsieh L.J., Rabbani F., Bach P.B., Herr H., and Begg C.B. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 95 (2003) 588
4. van Rhijn B.W., van der Poel H.G., and van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47 (2005) 736
5. Liou L.S. Urothelial cancer biomarkers for detection and surveillance. Urology 67 (2006) 25
6. Grossman H.B., Soloway M., Messing E., Katz G., Stein B., Kassabian V., et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295 (2006) 299
7. Grossman H.B., Messing E., Soloway M., Tomera K., Katz G., Berger Y., et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293 (2005) 810
8. Nam R.K., Redelmeier D.A., Spiess P.E., Sampson H.A., Fradet Y., and Jewett M.A. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis. J Urol 163 (2000) 752
9. Lotan Y., and Roehrborn C.G. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol 167 (2002) 75
10. Rodriguez-Rubio F., Sanz G., Garrido S., Sanchez C., and Estudillo F. Patient tolerance during outpatient flexible cystoscopy-a prospective, randomized, double-blind study comparing plain lubrication and lidocaine gel. Scand J Urol Nephrol 38 (2004) 477
11. Burke D.M., Shackley D.C., and O'Reilly P.H. The community-based morbidity of flexible cystoscopy. BJU Int 89 (2002) 347
12. Rashiq S., Edlund D., and Dick B.D. Utilities of the post-anesthesia state derived by the standard gamble method in surgical patients. BMC Med Inform Decision Making 6 (2006) 8
13. Vriesema J.L., Poucki M.H., Kiemeney L.A., and Witjes J.A. Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis. Urology 56 (2000) 793
14. Donat S.M., North A., Dalbagni G., and Herr H.W. Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol 171 (2004) 636
15. Bijur P.E., Latimer C.T., and Gallagher E.J. Validation of a verbally administered numerical rating scale of acute pain for use in the emergency department. Acad Emerg Med 10 (2003) 390
16. Droller M.J. Current concepts of tumor markers in bladder cancer. Urol Clin North Am 29 (2002) 229